Advertisement

Topics

MannKind Company Profile

22:01 EDT 21st September 2018 | BioPortfolio

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a proprietary dry powder formulation of Technosphere® insulin that is inhaled into the deep lung using our proprietary MedTone® inhaler. The inhaler is light, easy to use, and fits in the palm of the patient's hand, which is believed to facilitate patient compliance. We believe that the performance characteristics, unique kinetics, convenience and ease of use of the Technosphere® Insulin System may have the potential to change the way diabetes is treated. In particular, we have observed in our clinical trials to date that the Technosphere® Insulin System produces a profile of insulin levels in the bloodstream that approximates the insulin profile normally seen in healthy individuals immediately following the beginning of a meal, but which is absent in all patients with diabetes. As a result, we believe that our Technosphere Insulin System will be beneficial not only for insulin-using diabetes patients but also for patients with type 2 diabetes who are currently using conventional therapies other than insulin. If further clinical trials support our initial observations, we believe the Technosphere Insulin System has the potential to be indicated for the treatment of type 2 diabetes after a patient has failed to respond adequately to diet and exercise. The use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease.

Location

28903 North Avenue Paine
Valencia
California
91355
United States of America

Contact

Phone: (661) 775-5300


News Articles [93 Associated News Articles listed on BioPortfolio]

MannKind nets $26.6mm via RDO

MannKind Corp. netted $26.6mm through a registered direct offering of 14mm common shares at $2 each (a 16% discount) to institutional investors. The company also issued warrants to buy up to another 1...

Deals this week: MannKind, XtalPi, Ascendia Pharmaceuticals

Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug,...Read More... The post Deals this week: MannKind, XtalPi, ...

5 Top Weekly NASDAQ Biotech Stocks: MannKind Soars 83 Percent

MannKind, Evofem Biosciences, Arbutus Biopharma, Infinity Pharmaceuticals and VBI Vaccines were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Biotech Stocks:...

MannKind and United Therapeutics to advance dry powder treprostinil

US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation...Read More... The post MannKind and U...

MannKind signs distribution deal with Tanner for diabetes drug

US-based therapeutic products developer MannKind has signed an agreement with Tanner Pharma Group for the distribution of its Afrezza Inhalation...Read More... The post MannKind signs distribution dea...

‘Revamped’ MannKind secures $105m licensing deal, plans Afrezza expansion

MannKind Corporation, of Afrezza fame, and United Therapeutics have signed an exclusive licensing and collaboration agreement for dry powder pulmonary hypertension products.

Cipla gets Indian rights to MannKind's Afrezza

MannKind Corp. licensed Cipla Ltd. exclusive rights to market and distribute the Type I and II diabetes drug Afrezza (insulin) inhalation powder in India.

MannKind and United Therapeutics Ink $95 Million+ Deal

MannKind Corporation, based in Westlake Village, California, and United Therapeutics, located in Silver Spring, Maryland, signed a worldwide exclusive license and collaboration deal to develop and com...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its ...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product c...

MannKind Corporation and Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has use...

More Information about "MannKind" on BioPortfolio

We have published hundreds of MannKind news stories on BioPortfolio along with dozens of MannKind Clinical Trials and PubMed Articles about MannKind for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MannKind Companies in our database. You can also find out about relevant MannKind Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record